ClinVar Miner

Submissions for variant NM_000551.4(VHL):c.433_439del (p.Gln145fs) (rs1559428217)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 2
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Division of Genomic Diagnostics,The Children's Hospital of Philadelphia RCV000767272 SCV000897824 pathogenic Von Hippel-Lindau syndrome 2018-08-01 criteria provided, single submitter clinical testing
Laboratory for Molecular Medicine, Partners HealthCare Personalized Medicine RCV000767272 SCV001365786 likely pathogenic Von Hippel-Lindau syndrome 2019-03-26 criteria provided, single submitter clinical testing The p.Gln145PhefsX12 variant in VHL has not been previously reported in individuals with von Hippel-Lindau (VHL) syndrome or in large population studies. This variant is predicted to cause a frameshift, which alters the protein’s amino acid sequence beginning at position 145 and leads to a premature termination codon 12 amino acids downstream. This termination codon occurs within the terminal 50 bases of the second to last exon and is, therefore, likely to escape nonsense mediated decay (NMD) and result in a truncated protein. Different frameshift variants at this position (p.Gln145TyrfsX27, p.Gln145HisfsX28) have been reported in individuals with VHL syndrome (Stolle 1998, Peng 2017). Additionally, frameshift and other loss of function variants downstream of the p.Gln145PhefsX12 variant, including a truncating variant (p.Tyr175X) that has been determined to be pathogenic, have been reported in individuals with VHL syndrome (HGMD database, Stenson 2017), suggesting that this region of the VHL protein may play an important role in disease. In summary, although additional studies are required to fully establish its clinical significance, the p.Gln145PhefsX12 variant is likely pathogenic for autosomal dominant VHL syndrome based on predicted impact to the protein and absence from large population studies. ACMG/AMP Criteria applied: PVS1_Strong; PM2.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.